Recombinant allergens for immunotherapy: A Der p 2 variant with reduced IgE reactivity retains T-cell epitopes

Journal of Allergy and Clinical Immunology

Volumn 101, Issue 3, 1998, Pages 423-425

  Smith, Alisa M ^a   Chapman, Martin D ^b   Taketomi, Ernesto A ^b   Platts Mills, Thomas A E ^a   Sung, Sun Sang J ^b  

^a Asthma and Allergic Diseases Center   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; DER P 2; IMMUNOGLOBULIN E; RECOMBINANT DER P 2; RECOMBINANT DER P 2 C73 78 VARIANT; TETANUS TOXOID; UNCLASSIFIED DRUG;

ALLERGENICITY; ANTIBODY RESPONSE; ARTICLE; DNA RECOMBINATION; EDEMA; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INJECTION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031921016     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70259-3     Document Type: Article

References (5)

1. Creticos PS, Norman PS. Immunotherapy with allergens. JAMA 1987;258:2874-80.
2. Smith AM, Chapman MD. Allergen specific immunotherapy: new strategies using recombinant allergens. In: Bousquet J, Yssel H, editors. Immunotherapy for asthma. New York: Marcel Dekker, Inc. In press.
3. Smith AM, Chapman MD. Reduction in IgE binding to allergen variants generated by site directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen, Der p 2. Mol Immunol 1996;33:399-405.
4. Smith AM, Chapman MD. Localization of antigenic sites on Der p 2 using oligonucleotide-directed mutagenesis targeted to predicted surface residues. Clin Exp Allergy 1997;27:593-9.
5. Takai T, Yokota T, Yasue M, Nishiyama C, Yuuki T, Mori A, et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 1997;15:754-8.